| Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms … BP Howden, JK Davies, PDR Johnson, TP Stinear, ML Grayson Clinical microbiology reviews 23 (1), 99-139, 2010 | 1009 | 2010 |
| Treatment Outcomes for Serious Infections Caused by Methicillin-Resistant Staphylococcus aureus with Reduced Vancomycin Susceptibility BP Howden, PB Ward, PGP Charles, TM Korman, A Fuller, P Du Cros, ... Clinical Infectious Diseases 38 (4), 521-528, 2004 | 547 | 2004 |
| Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin-Intermediate Staphylococcus aureus PGP Charles, PB Ward, PDR Johnson, BP Howden, ML Grayson Clinical infectious diseases 38 (3), 448-451, 2004 | 439 | 2004 |
| Members of the Fusarium solani species complex that cause infections in both humans and plants are common in the environment N Zhang, K O'Donnell, DA Sutton, FA Nalim, RC Summerbell, AA Padhye, ... Journal of Clinical Microbiology 44 (6), 2186-2190, 2006 | 354 | 2006 |
| Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR BP Howden, CRE McEvoy, DL Allen, K Chua, W Gao, PF Harrison, J Bell, ... PLoS Pathog 7 (11), e1002359, 2011 | 268 | 2011 |
| Antibiotic Choice May Not Explain Poorer Outcomes in Patients With Staphylococcus aureus Bacteremia and High Vancomycin Minimum Inhibitory Concentrations NE Holmes, JD Turnidge, WJ Munckhof, JO Robinson, TM Korman, ... Journal of Infectious Diseases 204 (3), 340-347, 2011 | 248 | 2011 |
| Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia BP Howden, PDR Johnson, PB Ward, TP Stinear, JK Davies Antimicrobial Agents and Chemotherapy 50 (9), 3039-3047, 2006 | 239 | 2006 |
| Whole genome sequencing in clinical and public health microbiology JC Kwong, N McCallum, V Sintchenko, BP Howden Pathology 47 (3), 199-210, 2015 | 237 | 2015 |
| Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand JD Turnidge, D Kotsanas, W Munckhof, S Roberts, CM Bennett, ... Medical Journal of Australia 191 (7), 368-373, 2009 | 232 | 2009 |
| Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs ML Grayson, SM Crowe, JS McCarthy, J Mills, JW Mouton, SR Norrby, ... CRC Press, 2010 | 224* | 2010 |
| Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine BP Howden, MA Slavin, AP Schwarer, AM Mijch European Journal of Clinical Microbiology and Infectious Diseases 22 (2 …, 2003 | 208 | 2003 |
| Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection W Gao, K Chua, JK Davies, HJ Newton, T Seemann, PF Harrison, ... PLoS Pathog 6 (6), e1000944, 2010 | 204 | 2010 |
| Dumb and Dumber—The Potential Waste of a Useful Antistaphylococcal Agent: Emerging Fusidic Acid Resistance in Staphylococcus aureus BP Howden, ML Grayson Clinical Infectious Diseases 42 (3), 394-400, 2006 | 195 | 2006 |
| In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae A Poudyal, BP Howden, JM Bell, W Gao, RJ Owen, JD Turnidge, ... Journal of Antimicrobial Chemotherapy 62 (6), 1311-1318, 2008 | 181 | 2008 |
| Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia NE Holmes, JD Turnidge, WJ Munckhof, JO Robinson, TM Korman, ... Antimicrobial agents and chemotherapy 57 (4), 1654-1663, 2013 | 180 | 2013 |
| Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients E Bishop, S Melvani, BP Howden, PGP Charles, ML Grayson Antimicrobial agents and chemotherapy 50 (4), 1599-1602, 2006 | 178 | 2006 |
| Isolation and rapid sharing of the 2019 novel coronavirus (SARS‐CoV‐2) from the first patient diagnosed with COVID‐19 in Australia L Caly, J Druce, J Roberts, K Bond, T Tran, R Kostecki, Y Yoga, ... Medical Journal of Australia 212 (10), 459-462, 2020 | 170 | 2020 |
| Prospective whole-genome sequencing enhances national surveillance of Listeria monocytogenes JC Kwong, K Mercoulia, T Tomita, M Easton, HY Li, DM Bulach, ... Journal of clinical microbiology 54 (2), 333-342, 2016 | 163 | 2016 |
| Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns DA Williamson, GP Carter, BP Howden Clinical microbiology reviews 30 (3), 827-860, 2017 | 155 | 2017 |
| Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA-its evolving antimicrobial … K Chua, F Laurent, G Coombs, ML Grayson, BP Howden Clinical infectious diseases: an official publication of the Infectious …, 2011 | 155 | 2011 |
Tim StinearProfessor, University of MelbourneVerified email at unimelb.edu.au
